VistaGen Therapeutics Inc (VTGN) 0.8721 -0.01 (-0.9%)
0.8721 -0.01 (-0.9%)
US92840H2022 - Common Stock - After market: 0.87 0 (-0.24%)
Notable Monday Option Activity: AXSM, VTGN, NEWR
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
VistaGen to Participate in Upcoming June Investor Conferences
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains.
VistaGen Appoints Reid Adler as Chief Legal Officer
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage,...
VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to...
VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to...
August 2022 Options Now Available For VistaGen Therapeutics
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update
PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan ...
Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know
VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.